Abstract:Significance: Reactive oxygen species (ROS) are generated during mitochondrial oxidative metabolism, and are tightly controlled through homeostatic mechanisms to maintain intracellular redox, regulating growth and proliferation in healthy cells. However, ROS production is perturbed in cancers where abnormal accumulation of ROS leads to oxidative stress and genomic instability, triggering oncogenic signaling pathways on one hand, while increasing oxidative damage and triggering ROS-dependent death signaling on the other. Recent Advances: Our review illuminates how critical interactions between ROS and oncogenic signaling, the tumor microenvironment, and DNA damage response (DDR) pathways have led to interest in ROS modulation as a means of enhancing existing anticancer strategies and developing new therapeutic opportunities. Critical Issues: ROS equilibrium exists via a delicate balance of pro-oxidant and antioxidant species within cells. "Antioxidant" approaches have been explored mainly in the form of chemoprevention, but there is insufficient evidence to advocate its routine application. More progress has been made via the "pro-oxidant" approach of targeting cancer vulnerabilities and inducing oxidative stress. Various therapeutic modalities have employed this approach, including direct ROS-inducing agents, chemotherapy, targeted therapies, DDR therapies, radiotherapy, and immunotherapy. Finally, emerging delivery systems such as "nanosensitizers" as radiotherapy enhancers are currently in development. Future Directions: While approaches designed to induce ROS have shown considerable promise in selectively targeting cancer cells and dealing with resistance to conventional therapies, most are still in early phases of development and challenges remain. Further research should endeavor to refine treatment strategies, optimize drug combinations, and identify predictive biomarkers of ROS-based cancer therapies.

Reactive oxygen species-powered cancer immunotherapy: Current status and challenges

Reactive oxygen species-upregulating nanomedicines towards enhanced cancer therapy

Reactive Oxygen Species in Anticancer Immunity: A Double-Edged Sword

Reactive Oxygen Species Modulation in the Current Landscape of Anticancer Therapies

Induction of Reactive Oxygen Species: an Emerging Approach for Cancer Therapy

Targeting Reactive Oxygen Species Capacity of Tumor Cells with Repurposed Drug as an Anticancer Therapy

Precise modulation and use of reactive oxygen species for immunotherapy

Targeting ROS in cancer: rationale and strategies

Reactive Oxygen Species‐Mediated Pyroptosis with the Help of Nanotechnology: Prospects for Cancer Therapy

The Integration of Reactive Oxygen Species Generation and Prodrug Activation for Cancer Therapy

Reactive Oxygen Species Regulate T Cell Immune Response in the Tumor Microenvironment

Oxidative Stress in Cancer Immunotherapy: Molecular Mechanisms and Potential Applications

ROS in cancer therapy: the bright side of the moon

Roles of Reactive Oxygen Species in Inflammation and Cancer

Mechanisms and applications of radiation-induced oxidative stress in regulating cancer immunotherapy

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy

Reactive Oxygen Species-Based Nanomaterials for Cancer Therapy

Dissecting the pleiotropic roles of reactive oxygen species (ROS) in lung cancer: From carcinogenesis toward therapy

Novel Strategies for Tumor Treatment: Harnessing ROS-Inducing Active Ingredients from Traditional Chinese Medicine Through Multifunctional Nanoformulations

Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements

Promoting Reactive Oxygen Species Generation: a Key Strategy in Nanosensitizer-Mediated Radiotherapy